South Korea’s Ministry of Food and Drug Safety (MFDS) approved Curocell’s Rimqarto (anbalcabtagene-autoleucel; anbal-cel) as the first homegrown CAR T therapy for patients with advanced diffuse large B-cell lymphomas. The approval marks a milestone for domestic CAR-T development in a segment long dominated by global players. Rimqarto’s authorization positions Curocell to compete on local manufacturing and regulatory execution as CAR-T adoption continues to expand across oncology indications. The “first homegrown” framing also signals that national regulators and payers may be more willing to support additional localized cell therapy programs. For biotech teams, the key operational angle is timing: MFDS clearance indicates that South Korea can now point to a successful precedent for future approvals of similar next-generation CAR-T candidates.